Round 1 Winners!
Proof of Usefulness Report

Skin Analytics

Analysis completed on 3/13/2026

+693.81
Proof of Usefulness Score
Category Standard

Skin Analytics demonstrates exceptional real-world utility and technical innovation as a Class III CE marked AI medical device deployed within the NHS. With 170,000 patients processed, 15,500 identified cancers, and significant operational scale (350 employees), the project presents highly verifiable enterprise traction. The evaluation penalizes the response quality slightly due to casually filled secondary fields (e.g., 'everyone', 'most people'), but the core clinical impact and regulatory achievements solidly place this in the upper echelon of tech projects.

Ready to Compete for $150k+ in Prizes?

Move this data into a HackerNoon blog draft to become eligible for your share of $150k+ in cash and software prizes

View All Reports

Score Breakdown

Real World Utility+318.75
Audience Reach Impact+80.00
Technical Innovation+202.50
Evidence Of Traction+125.00
Market Timing Relevance+80.00
Functional Completeness+10.00
Subtotal+816.25
Usefulness Multiplierx0.85
Final Score+694

Project Details

Description
We’re working for a world where no one dies from skin cancer by deploying our AI medical device, DERM, to create the world’s most advanced skin cancer pathways. Skin Analytics are proud to work with NHS dermatology teams to deploy AI powered skin cancer pathways. Our pathways enable NHS organisations to discharge benign lesions earlier in the pathway and therefore tackle backlog, free up out-patient delays and crucially, reserve limited dermatology capacity to prioritise patients with skin cancer by focusing on providing potentially life-saving treatment. Some things we’re a little bit proud of: 🚀We’ve worked with the NHS since 2020 and DERM is currently deployed across 25 primary and secondary care organisations 🥇We’re the first and only AI skin cancer pathway within the NHS ✅ DERM is recommended by the National Institute for Health and Care Excellence (NICE) ✅DERM is the only Class III CE marked AI as a Medical Device for skin cancer 🤯DERM is used in pathways that have seen over 170,000 NHS patients and identified more than 15,500 cancers 💪We’ve helped NHS organisations avoid up to 95% of face-to-face appointments in secondary care 🤳We provide Bupa and Vitality's remote skin assessment service ❤️Everything we do is in pursuit of better patients outcomes that are sustainable for health systems, globally

Algorithm Insights

Market Position
Strong market validation with clear user adoption patterns
User Engagement
Documented reach suggests active user community
Technical Stack
Modern tech stack aligned with sponsor technologies

Recommendations to Increase Usefulness Score

Document User Growth

Provide specific metrics on user acquisition and retention rates

Showcase Revenue Model

Detail sustainable monetization strategy and current revenue streams

Expand Evidence Base

Include testimonials, case studies, and third-party validation

Technical Roadmap

Share development milestones and feature completion timeline